Following recognition by antibody and complement activation, C3b and C4b fragments accumulate on foreign targets. Autologous cells can also be attacked by complement, for example when recognized by autoantibodies. Moreover, the alternative and classical complement pathways are probably constantly turning over under physiological conditions. Whenever nascent C3b is generated, it is likely that some molecules can bind to autologous cells in the proximity. Until a few years ago the mechanisms of control of the C3b or C4b bound to autologous cells were obscure. Recent evidence from several laboratories indicates that the activities of these complement fragments are inhibited by specific membrane molecules. Two of them have been identified, the complement receptor type 1 (CR1) and the decay-accelerating factor (DAF). There is also growing suspicion that there are additional control proteins on the surfaces of mammalian cells, designed to inhibit the function of components of the membrane attack complex. Our long term objective is to study the structure and function of the components of this new family of complement inhibitors, and to devise methods to modulate their activity within the cell membrane.
Our specific aims are: A) To clarify the mechanisms of control of the activities of C3b and C4b bound to autologous cells. B) To study the structure and function of DAF and of the DAF variants found in extracellular fluids and cell membranes. C) To study the nature of the molecular defect which leads to the DAF deficiency observed in patients with paroxysmal nocturnal hemoglobinuria (PNH). If the membrane control proteins are identified, and their functional properties are known, we should be able to influence, and perhaps control, the outcome of the """"""""in vitro"""""""" attack by complement. Interesting applications can be foreseen, such as the destruction of selected populations of cells from samples of bone marrow preceding their transplantation into a patient.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI008499-23
Application #
3480461
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1976-05-01
Project End
1991-08-31
Budget Start
1990-09-01
Budget End
1991-08-31
Support Year
23
Fiscal Year
1990
Total Cost
Indirect Cost
Name
New York University
Department
Type
Schools of Medicine
DUNS #
004514360
City
New York
State
NY
Country
United States
Zip Code
10012
Tomlinson, S; Whitlow, M B; Nussenzweig, V (1994) A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9. J Immunol 152:1927-34
Tomlinson, S; Pontes de Carvalho, L C; Vandekerckhove, F et al. (1994) Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to complement. J Immunol 153:3141-7
Whitlow, M; Iida, K; Marshall, P et al. (1993) Cells lacking glycan phosphatidylinositol-linked proteins have impaired ability to vesiculate. Blood 81:510-6
Iida, K; Whitlow, M B; Nussenzweig, V (1991) Membrane vesiculation protects erythrocytes from destruction by complement. J Immunol 147:2638-42
Iida, K; Ley, V (1991) Isolation and characterization of a 92-KD surface molecule of Trypanosoma cruzi amastigotes recognized by a monoclonal antibody that induces complement-mediated killing. Am J Trop Med Hyg 45:619-28
Whitlow, M B; Iida, K; Stefanova, I et al. (1990) H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. Cell Immunol 126:176-84
Iida, K; Whitlow, M B; Nussenzweig, V (1989) Amastigotes of Trypanosoma cruzi escape destruction by the terminal complement components. J Exp Med 169:881-91
Davitz, M A; Hom, J; Schenkman, S (1989) Purification of a glycosyl-phosphatidylinositol-specific phospholipase D from human plasma. J Biol Chem 264:13760-4
Davitz, M A; Gurnett, A M; Low, M G et al. (1987) Decay-accelerating factor (DAF) shares a common carbohydrate determinant with the variant surface glycoprotein (VSG) of the African Trypanosoma brucei. J Immunol 138:520-3
Caras, I W; Davitz, M A; Rhee, L et al. (1987) Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 325:545-9

Showing the most recent 10 out of 15 publications